From The Editor

  1. Complex Protein Development: Assay Early, Assay Often 9/6/2024

    Experts from FyoniBio, SOTIO, and Vera Therapeutics weigh in with first-hand experience on how process decisions made very early on can influence – beneficially or detrimentally – the efficiency of upstream and even downstream operations in the development of novel protein therapeutics.

  2. Delivering Large Molecules To The CNS, Overcoming The Blood-Brain Barrier 8/29/2024

    Aliada Therapeutics' CSO, John Dunlop, Ph.D., explains the company's blood-brain barrier-crossing delivery platform for large molecules.

  3. Key Takeaways From The 2024 Bioprocessing Summit 8/26/2024

    Editor Tyler Menichiello reflects on the topics and trends covered at this year's Bioprocessing Summit in Boston.

  4. The ADC Market Is Ripening For Disruption 8/21/2024

    Where there is therapeutic demand, the industry will build capacity. But with ADCs, cytotoxic payloads and a fragmented contract manufacturing landscape make the path to clinical and commercial supply dauntingly complicated. Here's how the ADC manufacturing market is shaping up, and how it might ultimately shake out.

  5. Are You Taking The HPCs In Your ADCs Seriously? 8/16/2024

    The wave of ADC (antibody-drug conjugate) development and manufacturing activity we’re currently witnessing, and importantly, the HPC (high-potency compounds) comprising the payloads in these therapies, demand thorough assessment of development and manufacturing facility design.

  6. Are Bioprocess Equipment Standards A One-Sided Conversation? 7/31/2024

    Half of respondents to a recent survey of biopharmaceutical companies said the greatest challenge in further growing industry acceptance of single-use technology—which now comprises an eye-popping 85% of non-commercial-scale biopharma manufacturing infrastructure—is the greater challenge in further growing industry acceptance of single-use technology

  7. Integrating Analytics And Automation In Cell Therapy Manufacturing 7/31/2024

    Experts from last month’s Cell & Gene Live event discuss practical ways to utilize emerging technologies.

  8. The Patchwork Of Outsourced ADC Manufacturing 7/29/2024

    Antibody-drug conjugate (ADC) manufacturing is complicated, to say the least, and it relies on a diversity of expertise. In a recent Bioprocess Online Live event, Chief Editor Matt Pillar talks with expert panelists about how this unique modality requires unique manufacturing considerations.

  9. BPSA's Single-Use Summit Celebrates Its "Stainless" Anniversary 7/29/2024

    The Bio Process Systems Alliance (BPSA) is devoted to the advance of single-use technologies in biopharmaceutical manufacturing. At its 11th International Single-Use Summit, the explosive growth in single-use was on full display, and the sourcing, safety, sustainability, and application discussions on the agenda were comprehensive.

  10. Manufacturing CAR-T In Vivo 7/25/2024

    Manufacturing chimeric antigen receptor (CAR) T-cell therapies is a costly and complicated process. Interius BioTherapeutics is on a mission to reduce this complexity and get these therapies to patients faster — by manufacturing CAR T/NK cells in patients' bodies.